Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 816

1.

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.

Francardo V, Geva M, Bez F, Denis Q, Steiner L, Hayden MR, Cenci MA.

Neurotherapeutics. 2019 Feb 12. doi: 10.1007/s13311-018-00699-9. [Epub ahead of print]

PMID:
30756361
2.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565. [Epub ahead of print]

PMID:
30575996
3.

Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance.

Martin DDO, Schmidt ME, Nguyen YT, Lazic N, Hayden MR.

FASEB J. 2018 Nov 13:fj201701510RRR. doi: 10.1096/fj.201701510RRR. [Epub ahead of print]

PMID:
30423259
4.

Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.

Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA.

Mol Neurobiol. 2018 Oct 17. doi: 10.1007/s12035-018-1393-1. [Epub ahead of print]

PMID:
30334188
5.

Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.

Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, Seth PP, Raymond LA, Frank Bennett C, Hayden MR.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaar3959. doi: 10.1126/scitranslmed.aar3959.

PMID:
30282695
6.

Therapeutic approaches to Huntington disease: from the bench to the clinic.

Caron NS, Dorsey ER, Hayden MR.

Nat Rev Drug Discov. 2018 Oct;17(10):729-750. doi: 10.1038/nrd.2018.133. Epub 2018 Sep 21. Review.

PMID:
30237454
7.

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone.

Melamed-Gal S, Loupe P, Timan B, Weinstein V, Kolitz S, Zhang J, Funt J, Komlosh A, Ashkenazi N, Bar-Ilan O, Konya A, Beriozkin O, Laifenfeld D, Hasson T, Krispin R, Molotsky T, Papir G, Sulimani L, Zeskind B, Liu P, Nock S, Hayden MR, Gilbert A, Grossman I.

eNeurologicalSci. 2018 May 30;12:19-30. doi: 10.1016/j.ensci.2018.05.006. eCollection 2018 Sep.

8.

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG.

Cardiovasc Diabetol. 2018 Jul 30;17(1):108. doi: 10.1186/s12933-018-0750-8.

9.

Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.

Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Clin Pharmacol Ther. 2019 Feb;105(2):402-410. doi: 10.1002/cpt.1179. Epub 2018 Aug 17.

PMID:
29999516
10.

Huntington Disease.

Caron NS, Wright GEB, Hayden MR.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
1998 Oct 23 [updated 2018 Jul 5].

11.

Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.

Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR.

BMC Biol. 2018 Jun 27;16(1):58. doi: 10.1186/s12915-018-0526-3.

12.

A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease.

Martin DDO, Kay C, Collins JA, Nguyen YT, Slama RA, Hayden MR.

Sci Rep. 2018 May 25;8(1):8096. doi: 10.1038/s41598-018-25903-w.

13.

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.

Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR.

Mol Neurodegener. 2018 May 21;13(1):25. doi: 10.1186/s13024-018-0259-3.

14.

A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.

Petrella LI, Castelhano JM, Ribeiro M, Sereno JV, Gonçalves SI, Laço MN, Hayden MR, Rego AC, Castelo-Branco M.

Hum Mol Genet. 2018 Jun 15;27(12):2125-2137. doi: 10.1093/hmg/ddy119.

PMID:
29668904
15.

Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli.

Ladha S, Qiu X, Casal L, Caron NS, Ehrnhoefer DE, Hayden MR.

Cell Death Discov. 2018 Mar 12;4:40. doi: 10.1038/s41420-018-0043-8. eCollection 2018.

16.

Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.

Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR.

Acta Neuropathol Commun. 2018 Mar 6;6(1):16. doi: 10.1186/s40478-018-0518-0.

17.

Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice.

Chevre R, Trigueros-Motos L, Castaño D, Chua T, Corlianò M, Patankar JV, Sng L, Sim L, Juin TL, Carissimo G, Ng LFP, Yi CNJ, Eliathamby CC, Groen AK, Hayden MR, Singaraja RR.

FASEB J. 2018 Jul;32(7):3792-3802. doi: 10.1096/fj.201701084RR. Epub 2018 Feb 26.

PMID:
29481310
18.

The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population.

Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, Greenberg JL, Krause A, Hayden MR.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):346-357. doi: 10.1002/ajmg.b.32618. Epub 2018 Feb 20.

PMID:
29460498
19.

Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients.

Drögemöller BI, Brooks B, Critchley C, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Hayden MR, Gelmon KA, Carleton BC, Ross CJD.

Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. doi: 10.1158/1078-0432.CCR-17-2810. Epub 2018 Jan 22.

PMID:
29358504
20.

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA.

JCI Insight. 2017 Dec 7;2(23). pii: 95665. doi: 10.1172/jci.insight.95665. [Epub ahead of print]

21.

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model.

Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, Krispin R, Papir G, Sahly Y, Hayden MR.

Ann N Y Acad Sci. 2017 Nov;1407(1):75-89. doi: 10.1111/nyas.13547.

PMID:
29168242
22.

HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.

Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, Waltl S, Anderson L, Fazeli A, Casal L, Felczak B, Tsang M, Hayden MR.

Hum Mol Genet. 2018 Jan 15;27(2):239-253. doi: 10.1093/hmg/ddx394.

23.

Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition.

Patankar JV, Wong CK, Morampudi V, Gibson WT, Vallance B, Ioannou GN, Hayden MR.

Am J Physiol Endocrinol Metab. 2018 May 1;314(5):E418-E432. doi: 10.1152/ajpendo.00172.2017. Epub 2017 Oct 24.

PMID:
29066462
24.

Epidemiology of Huntington disease.

Kay C, Hayden MR, Leavitt BR.

Handb Clin Neurol. 2017;144:31-46. doi: 10.1016/B978-0-12-801893-4.00003-1. Review.

PMID:
28947124
25.

Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.

Silva AC, Ferreira IL, Hayden MR, Ferreiro E, Rego AC.

Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):34-44. doi: 10.1016/j.bbadis.2017.09.009. Epub 2017 Sep 20.

26.

ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels.

Trigueros-Motos L, van Capelleveen JC, Torta F, Castaño D, Zhang LH, Chai EC, Kang M, Dimova LG, Schimmel AWM, Tietjen I, Radomski C, Tan LJ, Thiam CH, Narayanaswamy P, Wu DH, Dorninger F, Yakala GK, Barhdadi A, Angeli V, Dubé MP, Berger J, Dallinga-Thie GM, Tietge UJF, Wenk MR, Hayden MR, Hovingh GK, Singaraja RR.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2147-2155. doi: 10.1161/ATVBAHA.117.309574. Epub 2017 Sep 7.

PMID:
28882873
27.

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.

Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR.

Genome Med. 2017 May 31;9(1):50. doi: 10.1186/s13073-017-0436-y.

28.

Xanthine oxidase inhibition protects against Western diet-induced aortic stiffness and impaired vasorelaxation in female mice.

Lastra G, Manrique C, Jia G, Aroor AR, Hayden MR, Barron BJ, Niles B, Padilla J, Sowers JR.

Am J Physiol Regul Integr Comp Physiol. 2017 Aug 1;313(2):R67-R77. doi: 10.1152/ajpregu.00483.2016. Epub 2017 May 24.

29.

Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.

Aroor AR, Habibi J, Kandikattu HK, Garro-Kacher M, Barron B, Chen D, Hayden MR, Whaley-Connell A, Bender SB, Klein T, Padilla J, Sowers JR, Chandrasekar B, DeMarco VG.

Cardiovasc Diabetol. 2017 May 5;16(1):61. doi: 10.1186/s12933-017-0544-4.

30.

Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC.

JAMA Oncol. 2017 Nov 1;3(11):1558-1562. doi: 10.1001/jamaoncol.2017.0502.

31.

Neurodegeneration: Role of repeats in protein clearance.

Martin DDO, Hayden MR.

Nature. 2017 May 4;545(7652):33-34. doi: 10.1038/nature22489. Epub 2017 Apr 26. No abstract available.

PMID:
28445458
32.

Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Ross CJD, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC.

Br J Clin Pharmacol. 2017 May;83(5):1143-1145. doi: 10.1111/bcp.13218. Epub 2017 Mar 19. No abstract available.

33.

Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.

Naia L, Cunha-Oliveira T, Rodrigues J, Rosenstock TR, Oliveira A, Ribeiro M, Carmo C, Oliveira-Sousa SI, Duarte AI, Hayden MR, Rego AC.

J Neurosci. 2017 Mar 8;37(10):2776-2794. doi: 10.1523/JNEUROSCI.2006-14.2016. Epub 2017 Jan 25.

34.

A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles.

Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, Slama R, Ooi J, Pouladi MA, Yang XW, Swayze EE, Seth PP, Hayden MR.

Hum Mol Genet. 2017 Mar 15;26(6):1115-1132. doi: 10.1093/hmg/ddx021.

PMID:
28104789
35.

Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population.

Hayden MR, Kay C.

Neurology. 2017 Jan 17;88(3):334-335. doi: 10.1212/WNL.0000000000003528. No abstract available.

PMID:
28093515
36.

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.

Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG.

Cardiovasc Diabetol. 2017 Jan 13;16(1):9. doi: 10.1186/s12933-016-0489-z.

37.

The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America.

Kay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins JA, Wright G, Inca-Martinez M, Veliz-Otani D, Ketelaar ME, Slama RA, Ross CJ, Mazzetti P, Hayden MR.

Eur J Hum Genet. 2017 Feb;25(3):332-340. doi: 10.1038/ejhg.2016.169. Epub 2016 Dec 21.

38.

Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice.

Sanders SS, Parsons MP, Mui KK, Southwell AL, Franciosi S, Cheung D, Waltl S, Raymond LA, Hayden MR.

BMC Biol. 2016 Dec 7;14(1):108.

39.

Daily exercise prevents diastolic dysfunction and oxidative stress in a female mouse model of western diet induced obesity by maintaining cardiac heme oxygenase-1 levels.

Bostick B, Aroor AR, Habibi J, Durante W, Ma L, DeMarco VG, Garro M, Hayden MR, Booth FW, Sowers JR.

Metabolism. 2017 Jan;66:14-22. doi: 10.1016/j.metabol.2016.09.005. Epub 2016 Sep 22.

PMID:
27923445
40.

Palmitoylation of caspase-6 by HIP14 regulates its activation.

Skotte NH, Sanders SS, Singaraja RR, Ehrnhoefer DE, Vaid K, Qiu X, Kannan S, Verma C, Hayden MR.

Cell Death Differ. 2017 Mar;24(3):433-444. doi: 10.1038/cdd.2016.139. Epub 2016 Dec 2.

41.

The global spectrum of protein-coding pharmacogenomic diversity.

Wright GEB, Carleton B, Hayden MR, Ross CJD.

Pharmacogenomics J. 2018 Jan;18(1):187-195. doi: 10.1038/tpj.2016.77. Epub 2016 Oct 25.

42.

eEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response.

Jan A, Jansonius B, Delaidelli A, Somasekharan SP, Bhanshali F, Vandal M, Negri GL, Moerman D, MacKenzie I, Calon F, Hayden MR, Taubert S, Sorensen PH.

Acta Neuropathol. 2017 Jan;133(1):101-119. doi: 10.1007/s00401-016-1634-1. Epub 2016 Oct 17.

PMID:
27752775
43.

Blood-Brain Barrier Disruption and Neurovascular Unit Dysfunction in Diabetic Mice: Protection with the Mitochondrial Carbonic Anhydrase Inhibitor Topiramate.

Salameh TS, Shah GN, Price TO, Hayden MR, Banks WA.

J Pharmacol Exp Ther. 2016 Dec;359(3):452-459. Epub 2016 Oct 11.

44.

Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.

Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, Grossman I, Knappertz V, Hayden MR, Laufer R.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6145-E6152. Epub 2016 Sep 26.

45.

Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models.

Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, Laço MN, Hayden MR, Oliveira CR, Rego AC.

Mol Neurobiol. 2017 Sep;54(7):5385-5399. doi: 10.1007/s12035-016-0048-3. Epub 2016 Sep 2.

PMID:
27590140
46.

Regular Exercise Reduces Endothelial Cortical Stiffness in Western Diet-Fed Female Mice.

Padilla J, Ramirez-Perez FI, Habibi J, Bostick B, Aroor AR, Hayden MR, Jia G, Garro M, DeMarco VG, Manrique C, Booth FW, Martinez-Lemus LA, Sowers JR.

Hypertension. 2016 Nov;68(5):1236-1244. Epub 2016 Aug 29.

47.

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA.

Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652.

48.

Pridopidine activates neuroprotective pathways impaired in Huntington Disease.

Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR.

Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27.

49.

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.

Manrique C, Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Martinez-Lemus LA, Ramirez-Perez FI, Klein T, Meininger GA, DeMarco VG.

Cardiovasc Diabetol. 2016 Jul 8;15:94. doi: 10.1186/s12933-016-0414-5.

50.

An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes.

Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, Raymond LA, Hayden MR.

Hum Mol Genet. 2016 Sep 1;25(17):3654-3675. doi: 10.1093/hmg/ddw212. Epub 2016 Jul 4.

Supplemental Content

Loading ...
Support Center